Celltrion, Nan Fung Group form JV to market Biosimilars in China
Korea headquartered Celltrion and Hong Kong based Nan Fung Group have announced the establishment of Vcell Healthcare Limited, a Joint Venture company between both parties.
At the formation of the Joint Venture, Vcell Healthcare Limited has simultaneously signed a licensing agreement with Celltrion Group. Vcell Healthcare Limited will obtain the exclusive rights in mainland China to develop, manufacture and commercialize three US FDA and EMA approved biosimilar products from Celltrion: CT-P13 (Remsima), CT-P10 (Truxima) and CT-P6 (Herzuma). Remsima, referencing Remicade (Infliximab), was the first antibody biosimilar approved in the EU and US